Clinical Trials Logo

Major Depressive Disorders clinical trials

View clinical trials related to Major Depressive Disorders.

Filter by:

NCT ID: NCT00855530 Completed - Clinical trials for Major Depressive Disorders

Long Term Safety and Tolerability of SR58611 in Patients With Major Depressive Disorder

Start date: September 2005
Phase: Phase 3
Study type: Interventional

Primary objective: - To evaluate the long-term safety and tolerability of SR58611A (amibegron) patients with major depressive disorder (MDD). Secondary objective: - To determine plasma concentrations of SR58878 (the active metabolite of SR58611A), for pharmacokinetic population analyses, to evaluate the quality of life (QoL) in patients with MDD, and to evaluate the efficacy of amibegron in patients with MDD.

NCT ID: NCT00825058 Completed - Clinical trials for Major Depressive Disorders

Efficacy and Safety of SR58611 Compared to Placebo and Paroxetine

Start date: November 2003
Phase: Phase 3
Study type: Interventional

Primary objective : - To demonstrate the antidepressant efficacy on the Hamilton Depression Rating Scale of SR58611A 700mg/day compared with placebo in the treatment of patients with a recurrent major depressive episode. Secondary objectives: - To assess the safety profile of SR58611A 700 mg/d in comparison to placebo and to assess plasma concentrations of the active metabolite.

NCT ID: NCT00825019 Completed - Clinical trials for Major Depressive Disorders

Efficacy and Safety of One Single Dose of SR58611 Compared to Placebo and Paroxetine

Start date: September 2003
Phase: Phase 3
Study type: Interventional

Primary objective is to demonstrate the antidepressant efficacy on the Hamilton depression rating scale (HAM-D) of amibegron (SR58611) 700 mg/day compared to placebo in the treatment of patients with a recurrent major depressive episode (MDD). Secondary objective is to assess the safety profile of amibegron 700 mg/d in comparison to placebo and to assess plasma concentrations of the active metabolite.